Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for patients with medical comorbidities and who are ineligible for surgery. In this context, stereotactic b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-10-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/02656736.2019.1647351 |
| _version_ | 1818357732101586944 |
|---|---|
| author | Jean Palussière Vittorio Catena Philippe Lagarde Sophie Cousin Mathilde Cabart Xavier Buy François Chomy |
| author_facet | Jean Palussière Vittorio Catena Philippe Lagarde Sophie Cousin Mathilde Cabart Xavier Buy François Chomy |
| author_sort | Jean Palussière |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for patients with medical comorbidities and who are ineligible for surgery. In this context, stereotactic body radiotherapy (SBRT) has demonstrated high efficacy in treating T1 NSCLC and will need to be compared with percutaneous ablation. TA is also indicated in oligoprogressive disease; and can be proposed as a salvage treatment option for tumor recurrence after radiotherapy. Besides more advanced NSCLC could be also an indication of TA in combination with systemic treatments. A large majority of diagnosed NSCLC do not exhibit specific targetable genetic aberration. Those tumors present poorer prognosis and have been treated with standard chemotherapy regimen until the recent development of immune checkpoint inhibitors (ICIs) based immunotherapy. Combining TA with immunotherapy is promising and still needs to be explored. |
| first_indexed | 2024-12-13T20:17:47Z |
| format | Article |
| id | doaj.art-5425cef5a4e14268b1a908744f7a9161 |
| institution | Directory Open Access Journal |
| issn | 0265-6736 1464-5157 |
| language | English |
| last_indexed | 2024-12-13T20:17:47Z |
| publishDate | 2019-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj.art-5425cef5a4e14268b1a908744f7a91612022-12-21T23:32:45ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572019-10-01362465210.1080/02656736.2019.16473511647351Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?Jean Palussière0Vittorio Catena1Philippe Lagarde2Sophie Cousin3Mathilde Cabart4Xavier Buy5François Chomy6Institut BergoniéInstitut BergoniéInstitut BergoniéInstitut BergoniéInstitut BergoniéInstitut BergoniéInstitut BergoniéNon-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for patients with medical comorbidities and who are ineligible for surgery. In this context, stereotactic body radiotherapy (SBRT) has demonstrated high efficacy in treating T1 NSCLC and will need to be compared with percutaneous ablation. TA is also indicated in oligoprogressive disease; and can be proposed as a salvage treatment option for tumor recurrence after radiotherapy. Besides more advanced NSCLC could be also an indication of TA in combination with systemic treatments. A large majority of diagnosed NSCLC do not exhibit specific targetable genetic aberration. Those tumors present poorer prognosis and have been treated with standard chemotherapy regimen until the recent development of immune checkpoint inhibitors (ICIs) based immunotherapy. Combining TA with immunotherapy is promising and still needs to be explored.http://dx.doi.org/10.1080/02656736.2019.1647351Non-small cell lung cancerthermal ablationradiofrequency ablationmicrowavescryoablation |
| spellingShingle | Jean Palussière Vittorio Catena Philippe Lagarde Sophie Cousin Mathilde Cabart Xavier Buy François Chomy Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? International Journal of Hyperthermia Non-small cell lung cancer thermal ablation radiofrequency ablation microwaves cryoablation |
| title | Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? |
| title_full | Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? |
| title_fullStr | Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? |
| title_full_unstemmed | Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? |
| title_short | Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? |
| title_sort | primary tumors of the lung should we consider thermal ablation as a valid therapeutic option |
| topic | Non-small cell lung cancer thermal ablation radiofrequency ablation microwaves cryoablation |
| url | http://dx.doi.org/10.1080/02656736.2019.1647351 |
| work_keys_str_mv | AT jeanpalussiere primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT vittoriocatena primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT philippelagarde primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT sophiecousin primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT mathildecabart primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT xavierbuy primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption AT francoischomy primarytumorsofthelungshouldweconsiderthermalablationasavalidtherapeuticoption |